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Abstract
Background: The association between lymphovascular invasion and lymphatic or hematogenous metastasis has
been suspected, with conflicting evidence. We have investigated the association between the risk of biochemical
recurrence and lymphovascular invasion in resection margin negative patients, as well as its association with lymph
node metastasis.
Methods: One thousand six hundred thirty four patients who underwent radical prostatectomy from 2005 to 2014
were selected. Patients with bone or distant organ metastasis at the time of operation were excluded. Survival
analysis was performed to assess biochemical recurrence, metastasis and mortality risks by Kaplan-Meier analysis
and multivariate Cox proportional hazard regression. Odds of lymph node metastasis were evaluated by Logistic
regression.
Results: LVI was detected in 118 (7.4%) patients. The median follow-up duration was 33.1 months. In the Kaplan-Meier
analysis, lymphovascular invasion was associated with significantly increased 5-year and 10-year BCR rate (60.2% vs.
39.1%, 60.2% vs. 40.1%, respectively; p < 0.001), 10-year bone metastasis rate and cancer specific mortality (16.9% vs.
5.1%, p = 0.001; 6.8% vs. 2.7%, p = 0.034, respectively) compared to patients without LVI. When stratified by T stage and
resection margin status, lymphovascular invasion resulted in significantly increased 10-year biochemical recurrence rate
in T3 patients both with and without positive surgical margin (p = 0.008, 0.005, respectively). In the multivariate
Cox regression model lymphovascular invasion resulted in 1.4-fold BCR risk and 1.7-fold metastasis risk increase
(95% CI 1.045–1.749, 1.024–2.950; p = 0.022, 0.040, respectively). Lymphovascular invasion was revealed to be strongly
associated with lymph node metastasis in the multivariate Logistic regression (OR 4.317, 95% CI 2.092–8.910, p < 0.001).
Conclusion: Lymphovascular invasion increases the risk of recurrence in T3 patients regardless of margin status, by
accelerating lymph node metastasis and distant organ metastasis.
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Background
The association between lymphovascular invasion and
lymphatic or hematogenous metastasis has been suspected
since 1994, when the College of American Pathologists
recommended to routinely report lymphovascular inva-
sion (LVI) for radical prostatectomy specimens; however,
current evidence remains controversial [1–5]. There are
several factors that make it difficult for LVI to establish its
value as an independent prognostic factor for recurrence.
Definitions of LVI vary from author to author, and there
are issues of overdetection with artifacts, all of which
contribute to the confusion regarding this particular
pathologic finding [6]. In other malignancies, such as thy-
roid [7], lung [8], stomach [9], bladder [10], kidney [11],
and breast cancers [12], LVI is considered as an independ-
ent prognostic factor. Regarding the prostate, despite the
unclear prognostic value of LVI in prior studies conducted
in the general population, more recent investigations of
patients in particular stages show some promising aspects
[1, 13, 14]. Although the migration of cancer cells into
vessels is generally regarded as a necessary early step for
nodal or distant metastasis in other cancers, evidence re-
mains scarce for the prostate cancer [2, 15].
Under the hypothesis that LVI is associated with
increased risk of recurrence by accelerating lymph node
metastasis, we have analyzed the association between LVI
and risk of biochemical recurrence (BCR) according to
pathologic T stage and resection margin status, as well as
its influence on the risk of lymph node metastasis.
Methods
Patient population
With approval from the institutional review board
(protocol number 4–2015-0829), data were collected by
reviewing medical charts in a retrospective fashion. 1634
patients who underwent the nerve-sparing radical pros-
tatectomy by a single surgeon (Y.D.C.) at our hospital
from 2005 to 2014 were selected. Informed consent from
the participants was waived by the institutional review
board. Patients with distant organ or bone metastasis
prior to the operation (n = 33) or missing records
(n = 1) were considered not appropriate for analysis
leaving 1600 patients in the cohort.
Histopathologic examination
LVI was assessed by a single board-certified pathologist
on all available hematoxylin and eosin-stained slides. LVI
was defined as the invasion of vessel walls by tumor cells
and/or the presence of tumor emboli within a definite
endothelial-lined space, at a distance from tumors, or in
the prostatic parenchyma surrounding the tumor. No
attempt was made to distinguish between blood vessels
and lymphatics due to the difficulty and lack of reprodu-
cibility. Only definite LVI was regarded as positive,
whereas equivocal or suspected LVI (tumor emboli ob-
served in a space with the appearance of a vessel but
without a recognizable endothelial lining) was regarded
as negative and considered artifacts due to peritumoral
edema and tissue shrinkage (Fig. 1). Based on previous
data showing that the use of immunohistochemical
markers for vascular and lymphatic channels did not im-
prove interobserver agreement in diagnosis of LVI [16],
we did not perform immunohistochemical staining to
determine the presence or absence of LVI. Bilateral pel-
vic lymph node dissection was performed at the time of
radical prostatectomy by the operating surgeon’s deci-
sion. Lymph node metastasis was confirmed according
to the final pathologic report.
Postoperative follow-up
A patient was considered to have reached BCR when the
postoperative prostate-specific antigen (PSA) level of
0.2 ng/mL above the nadir was detected after a nadir PSA
value of 0.1 ng/mL was reached. Regional recurrence or
distant organ metastasis detected on radiologic images
were considered as BCR events.
Radiologic examination
Annual or bi-annual postoperative follow-up with
abdomen-pelvis computed tomography (CT) was done to
detect unsuspected metastasis. Postoperatively developed
lymph node enlargements were counted as a part of
Fig. 1 Hematoxylin-Eosin stained microscopy images (×100) of (a) unequivocal and (b) equivocal cases. Tumor emboli observed in a space with
the appearance of a vessel but without a recognizable endothelial lining were considered equivocal
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distant organ metastasis. Patients with BCR or relevant
symptoms were screened for brain, lung, and bone metas-
tasis with whole body positron emission CT, chest CT,
and bone scintigraphy. Determination of distant organ or
bone metastasis was done based on the official reading by
institutional radiologists. Equivocal cases were confirmed
with following positron emission tomography– CT using
Fluorine-18 radiotracer or pelvis magnetic resonance
image. Time to metastasis was determined as the duration
from the operation date to the date of radiologic study
with a first identifiable metastatic lesion.
Statistical analysis
The Kaplan-Meier method was used to plot survival
functions, and differences were assessed with the pair-
wise log rank test. Multivariate survival analysis for
BCR was performed by constructing Cox proportional
hazard regression models. Odds for lymph node metasta-
sis were analyzed with Logistic regression. All statistical
analyses were performed using Statistical Package for So-
cial Sciences v.22.0 for Windows (SPSS, Chicago, Illinois).
A p-value <0.05 was considered statistically significant in
the current study.
Results
Baseline characteristics
Raw data are available as a Additional file 1. LVI was de-
tected in 118 (7.4%) patients. Baseline characteristics of
patients are as listed in Table 1. The median age was 66
(interquartile range [IQR] 61–71) and the median
follow-up duration was 33.1 (IQR 18.4–53.8) months.
Overall 666 (41.6%) patients were found to have BCR,
and 95 (5.9%) patients developed metastasis. Forty-eight
(3.0%) patients expired of prostate cancer.
Time-to-event analysis
Survival curves were plotted for BCR, bone metastasis,
and cancer-specific survival to demonstrate the impact
of LVI by Kaplan-Meier method as shown in the Fig. 2.
Presence of LVI significantly increased 5-year and 10-
year BCR rate compared to patients without LVI (60.2%
vs. 39.1%, 60.2% vs. 40.1%, respectively; p < 0.001). Ten-
year rate of metastasis and cancer-specific mortality was
also significantly higher in LVI group (16.9% vs. 5.1%,
p = 0.001; 6.8% vs. 2.7%, p = 0.034, respectively). When
stratified according to T stage and surgical margin status
(Fig. 3), LVI increased the risk of BCR independent of
the margin status in T3 patients. Not only LVI in T3
with negative margin patients increased the 10-year BCR
rate (59.1% vs. 36.4%, p = 0.008) to a level comparable
to T3 positive margin (vs. 60.4%, p = 0.937) or T4
patients (vs. 71.0%, p = 0.658), but also in T3 with posi-
tive margin, 10-year rate of BCR for LVI patients were
significantly higher than patients without LVI (76.5% vs.
59.1%, p = 0.005).
Cox proportional hazard regression
As LVI is renowned for its close association with adverse
prognostic factors, multivariate regression model was
constructed to control for their effect. On preliminary
univariate analysis, age, initial PSA ≥ 20 ng/mL, patho-
logic Gleason sum 7, ≥8, pathologic T stage 3, 4, PSM,
lymph node metastasis and LVI showed statistically sig-
nificant difference in BCR risk, as shown in Table 2. In
the following multivariate analysis, LVI resulted in 1.4-
fold increased risk of BCR (95% confidence interval [CI]
1.045–1.749, p = 0.022), when adjusted for factors found
significant in the univariate analysis, such as initial PSA,
pathologic T stage, pathologic Gleason sum, PSM, and
lymph node metastasis. While age showed significant as-
sociation in univariate analysis, it was found to be not
associated with risk increase when other known prog-
nostic factors were accounted for (p = 0.855). When
assessed for the risk of distant organ metastasis, univari-
ate analysis revealed age, PSA, T stage 4, Gleason score
7, ≥8, PSM, lymph node metastasis, and LVI to show
association. In the multivariate model, LVI significantly
increased the metastasis risk (hazard ratio [HR] 1.738,
Table 1 Baseline demographics
Median (IQR)/n(%)
Age (years) 66(61–71)
Initial PSA (ng/mL) 8.2(5.3–15.5)
Pathologic T stage 2 741(46.3)
3 825(51.6)
4 33(2.1)
Lymph node metastasis (−) 1555(97.2)
(+) 45(2.8)
Pathologic Gleason score ≤6 434(27.1)
7 780(48.8)
≥8 386(24.1)
LVI (−) 1482(92.6)
(+) 118(7.4)
Margin status (−) 840(52.5)
(+) 760(47.5)
BCR No 934(58.4)
Yes 666(41.6)
Distant metastasis Present 1505(94.1)
Absent 95(5.9)
Cancer-specific mortality Survived 1552(97.0)
Expired 48(3.0)
Follow-up duration (months) 33.1(18.4–53.8)
LVI lymphovascular invasion; PSA prostate-specific antigen; NHT neoadjuvant
hormone therapy; BCR biochemical recurrence
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95% CI 1.024–2.950, p = 0.040). There were no signifi-
cant associations for age, PSA, and PSM in the model,
while T stage 4, Gleason score ≥ 8, and lymph node me-
tastasis retained statistical significance.
Logistic regression for lymph node metastasis
To investigate the influence of LVI on the lymph node
metastasis, logistic regression was performed (Table 3).
Pathologic T stage above 3, LVI, PSM, PSA above 20 ng/
mL, pathologic Gleason score above 8 were significantly
associated with lymph node metastasis in the univariate
analysis (all p < 0.001). With the parameters found signifi-
cant in the univariate analysis, multivariate model was
constructed. Second to the Gleason score above 8 (odds
ratio [OR] 5.745, 95% CI 2.687–12.285, p < 0.001), LVI
was associated with high odds of concurrent lymph node
metastasis (OR 4.317, 95% CI 2.092–8.910, p < 0.001).
Elevated PSA above 20 ng/mL (OR 3.208 95% CI 1.647–
6.246, p = 0.001) and PSM (OR 3.697, 95% CI 1.462–
9.351, p = 0.006) were also associated with lymph node
metastasis. T3 stage did not show statistically significant
association in the multivariate analysis (p = 0.165).
Fig. 2 Kaplan-Meier curve for a BCR, b distant organ metastasis, c cancer-specific survival stratified by LVI
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Discussion
Our study is, to our knowledge, the largest to demon-
strate that LVI increases the recurrence risk in patients
with T3 tumors independent of resection margin status.
Our results indicate that increased BCR rate in LVI tu-
mors is mainly mediated by increased lymph node me-
tastasis, a cause different from residual cancer cells by
PSM cancers. Although previous studies generally agree
that LVI is associated with disease progression and ag-
gressive tumor behavior, its value as an independent
prognostic factor remains debatable. According to Loeb
et al., LVI was not an independent predictor of progres-
sion in a multivariate model, although it showed a sig-
nificant association with tumor volume, Gleason
score > 6, PSM, extraprostatic extension (EPE), positive
lymph nodes, and seminal vesicle invasion (SVI) [3].
Fig. 3 Kaplan-Meier curve for BCR stratified by T stage and PSM
Table 2 Cox regression for BCR and distant metastasis with LVI and other parameters as covariate
BCR Distant metastasis
Univariate Multivariate Univariate Multivariate
p-value HR 95% CI p-value p-value HR 95% CI p-value
Age (years) 0.001* 1.001 0.990–1.012 0.855 0.048* 1.023 0.992–1.055 0.149
Initial PSA (ng/mL) ≥20 <0.001* 2.230 1.867–2.662 <0.001* <0.001* 1.495 0.950–2.353 0.082
Pathologic T stage
3 <0.001* 1.522 1.253–1.849 <0.001* 0.103 0.704 0.409–1.212 0.205
4 <0.001* 1.707 1.094–2.664 0.019* <0.001* 2.399 1.026–5.611 0.043*
Pathologic Gleason score
7 <0.001* 1.953 1.521–2.508 <0.001* <0.001* 1.123 0.566–2.229 0.741
≥8 <0.001* 3.233 2.474–4.224 <0.001* <0.001* 3.284 1.670–6.454 0.001*
PSM <0.001* 2.125 1.775–2.543 <0.001* 0.005* 1.317 0.819–2.118 0.256
LVI <0.001* 1.352 1.045–1.749 0.022* <0.001* 1.738 1.024–2.950 0.040*
Lymph node metastasis <0.001* 1.459 1.035–2.056 0.031* <0.001* 5.083 2.954–8.749 <0.001*
LVI: lymphovascular invasion; PSM: positive surgical margin; PSA: prostate-specific antigen; NHT: neoadjuvant hormone therapy; HR: hazard ratio; CI:
confidence interval
*statistically significant at p < 0.05
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Shariat et al., in their study involving 630 patients, have
concluded that a correlation between BCR and LVI is
mediated via an association with established features of
biologically aggressive prostate cancer, and that LVI is a
lethal phenotype of prostate cancer, leading to early me-
tastasis and lower overall survival [2]. A close association
of LVI with features of aggressive disease were
highlighted again in the study by Yee et al. Whereas LVI
was shown to have an independent prognostic value of
its own in multivariate analysis, only marginal improve-
ment was noted with the addition of LVI in the model,
rendering the parameter not clinically meaningful [4].
Conversely, other evidence suggests that LVI is an inde-
pendent prognostic factor, aside from its close association
with the features of disease aggressiveness. Cheng et al. re-
ported LVI to be an independent prognostic factor of BCR
and cancer-specific survival for clinically localized prostate
cancer patients, increasing BCR risk by 1.6 fold in their
multivariate model (95% CI 1.12–2.38) [15]. Similarly,
May et al. found that in addition to high Gleason score
(HR 3.51, 95% CI 2.06–6.00), LVI is the factor that signifi-
cantly increases the BCR risk for organ confined cancer
patients (HR 4.39, 95% CI 2.47–7.80) [5]. Our results from
Kaplan-Meier analysis indicate that LVI increases BCR
rate and cancer-specific mortality up to 20% and 5%,
respectively (Fig. 2). Controlling for the other known pa-
rameters, our regression model found LVI to retain statis-
tical significance in its association with increased BCR risk
(HR 1.352, 95% CI 1.045–1.749, p = 0.022). This disproves
the belief that the increased recurrences in the LVI
patients are due to the strong association with other estab-
lished prognostic factors.
Especially in the cancers of T3 stage, we identified that
there exists difference in the pattern of disease progres-
sion between LVI positive and negative patients. Radical
prostatectomy has been not recommended on T3 patient
up until recently as it was reported to be rarely curative
[17]. However, from several randomized clinical trials,
operation is now proven to be a valid option as it grants
improved survival benefit in T3 patients [18]. Among
the factors associated with recurrence risk, incomplete
resection and unsuspected lymph node metastasis re-
mains a major obstacle [17]. PSM suggests the presence
of remnant cancer in the prostate bed, whether viable or
not [19, 20]. It is recognized as a strong predictive factor
for BCR, and attempting regional control with radiother-
apy is known to yield favorable results [21]. Along with
PSM, LVI is reported to increase BCR as well in T3 pa-
tients. Herman et al. evaluated pT3N0 disease and found
that LVI was an independent predictor of disease recur-
rence [13]. Similar conclusions were drawn from the
studies by Yamamoto et al. and Epstein et al., where LVI
was found to be an independent prognostic factor in
pT3a and pT3b tumors, respectively [1, 14]. Our results
indicate that both PSM and LVI increase BCR risk, but
in an independent manner. Presence of LVI significantly
increased BCR rate in both positive and negative resec-
tion margin T3 groups (Fig. 3) as well as in multivariate
model with PSM as a covariate (Table 2). It was shown
by Mitsuzuka et al. that, LVI can increase BCR risk with-
out PSM in T2 patients (p < 0.001, HR 3.809) [22]. Our
result extends the finding to T3 cancers, adding to the
evidence that mechanism by which cancer progresses for
LVI positive cancer is different from PSM cancer where
local tumor recurrence is believed to be a major cause of
treatment failure [23].
LVI may serve as a portal of entry for systemic pro-
gress via regional lymph nodes. Liauw et al. [24] in the
study on the role of of SVI and LVI for salvage radio-
therapy patients, they demonstrated that LVI was associ-
ated with increased risk of BCR after radiotherapy
(p = 0.019) and resulted in treatment failure in all
patients, concluding that salvage radiotherapy was inef-
fective in LVI patients. It is likely that this is due to
metastatic regions being present beyond the coverage of
radiotherapy but currently, little is known about the
association between LVI and metastasis regarding pros-
tate cancer. Cheng et al. reported increased rate of LVI
in lymph node metastasis patients (61% vs. 20%,
p < 0.0001), but the evidence was inconclusive as LVI
was also increased in patients with several other estab-
lished prognostic factors [15]. Shariat et al. also sug-
gested the association between LVI and lymph node
metastasis by demonstrating that 5-year metastasis free
rate was significantly lower as 63.0% in LVI group, com-
pared to 96.7% in no LVI group [2]. In search of
Table 3 Odds of LVI for lymph node metastasis analyzed by multivariate logistic regression
Univariate Multivariate
p-value OR 95% CI p-value
PSA (ng/mL) ≥20 <0.001* 3.208 1.647-6.246 0.001*
Pathologic T stage ≥3 <0.001* 2.216 0.722-6.803 0.165
Pathologic Gleason score ≥8 <0.001* 5.745 2.687-12.285 <0.001*
PSM <0.001* 3.697 1.462-9.351 0.006*
LVI <0.001* 4.317 2.092-8.910 <0.001*
LVI lymphovascular invasion; PSM positivie surgical margin; PSA prostate-specific antigen;OR odds ratio;CI confidence interval
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association between LVI and metastasis, we identified
that LVI is associated with increased 10-year distant
organ metastasis rate (16.9% vs. 5.1%, p = 0.001). The as-
sociation was independent of other prognostic factors in
the multivariate analysis (HR 1.738, 95% CI 1.024–2.950;
p = 0.040), and we speculate that increased progression
to metastatic disease stems from the early access to
lymphatic channel, as LVI (OR 4.317, 95% CI 2.092–
8.910, p < 0.001) was strongly associated with concomi-
tant lymph node metastasis in our Logistic regression
model (Table 3). Only parameter to show stronger asso-
ciation than LVI was Gleason score ≥ 8 (OR 5.745),
which is a well-known prognostic factor of lymph node
metastasis [25]. According to our results, occult metas-
tasis should be suspected when LVI is detected, and me-
ticulous follow-up examinations for the evidence of
metastasis should be ready.
Our study has some important limitations. Firstly, no
discrimination between lymphatic and vascular invasion
has been made. While it is possible to identify blood ves-
sels from the lymphatic channel by immunohistochemi-
cal analysis, its clinical significance is not clear, and we
have made no effort in describing the nature of vessels
[6]. In addition, due to the retrospective nature of our
study, radiologic images were interpreted by several
other radiologists, allowing possible inter-observer varia-
tions. Utilization of pre-set criteria in the prospective
setting may improve accuracy of results.
Conclusion
LVI increased the risk of recurrence in T3 patients inde-
pendent of margin status. With its close association to
lymph node metastasis, occult metastasis via lymphatic
channel should be suspected in patients with LVI.
Additional file
Additional file 1: Raw patient parameters used in the analysis.
(XLSX 164 kb)
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